BACKGROUND INFORMATION ON THE PROCEDURE 
1. 
Submission of the dossier 
The company Centocor B.V. submitted on 5 March 1998 an application for Marketing Authorisation to 
the European Agency for the Evaluation of Medicinal Products (EMEA) for Remicade, in accordance 
with the centralised procedure falling within the scope of Part A of the Annex to Council Regulation 
No (EEC) 2309/93 of 22 July 1993. 
The Rapporteur and Co-Rapporteur appointed by the CPMP were: 
Rapporteur:  Dr. P. Sjöberg 
Co-Rapporteur:  Dr. M. Haase 
Licensing status: 
The product was not licensed in any country at the time of submission of the application. 
2. 
• 
• 
• 
• 
• 
• 
• 
• 
• 
• 
• 
Steps taken for the assessment of the product 
The procedure started on 27 March 1998. 
The Rapporteur's first assessment report was circulated to all CPMP Members on 8 June 1998. 
The  Co-Rapporteur's  first  assessment  report  was  circulated  to  all  CPMP  Members  on  
3 June 1998. 
During the meeting on 21 July 1998 the CPMP agreed on the consolidated list of questions to be 
sent  to  the  company.  The  final  consolidated  list  of  questions  was  sent  to  the  company  on 
22 July 1998. 
The  company  submitted 
30 November 1998. 
the 
responses 
to 
the  consolidated 
list  of  questions  on  
The  Rapporteur/Co-Rapporteur  circulated  the  response  assessment  report  on  the  company’s 
responses to the list of questions to all CPMP Members on 25 January 1999. 
The CPMP during their meeting on 24 February 1999 discussed the joint assessment report and 
decided 
in  March.  
the  clock  for  an  oral  presentation  on  clinical 
A list of outstanding clinical and quality issues was adopted by the CPMP.  
to  stop 
issues 
Oral  explanations  were  given  by  the  Applicant  on  23  March  1999.  The  CPMP  decided  to 
convene  an  expert  group  to  address  specific  clinical  points  (ANNEX  4.6).  Supplementary 
information with reference to ongoing studies on safety and post-marketing data on efficacy was 
requested from the applicant. 
The BWP during their meeting on 11 May 1999 prepared a recommendation to the CPMP on the 
outstanding quality aspects. 
An ad-hoc experts group meeting took place on 17 May 1999 to address open clinical issues on 
Remicade. The group prepared a recommendation to the CPMP on these issues. 
During the meeting on 18-20 May 1999 the CPMP, in the light of the overall data submitted and 
the  scientific  discussion  within  the  Committee,  issued  a  positive  opinion  for  granting  a 
Marketing Authorisation to Remicade on 19 May 1999. 
The  CPMP  opinions  were  forwarded,  in  all  official  languages  of  the  European  Union,  to  the 
European Commission, which adopted the corresponding Decisions on 13 August 1999. 
1/1 
EMEA 2005 
 
 
